Sangamo enters into asset sale agreements with Lilly and Astellas

Click here to view

Additional information about the Chapter 11 reorganization and asset sales is available through Sangamo's noticing agent at https://www.veritaglobal.net/SangamoTherapeutics.

Presentation

Presentation: A combined fertility, embryofetal development, AAV integration and germline transmission risk study in mice with ST-920 (isaralgagene civaparvovec) for Fabry disease

Download PDF